WO2020259478A1 - Tricyclic compound as prmt5 inhibitor and application thereof - Google Patents
Tricyclic compound as prmt5 inhibitor and application thereof Download PDFInfo
- Publication number
- WO2020259478A1 WO2020259478A1 PCT/CN2020/097652 CN2020097652W WO2020259478A1 WO 2020259478 A1 WO2020259478 A1 WO 2020259478A1 CN 2020097652 W CN2020097652 W CN 2020097652W WO 2020259478 A1 WO2020259478 A1 WO 2020259478A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- acyl
- group
- amino
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 130
- 229940125897 PRMT5 inhibitor Drugs 0.000 title 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 claims abstract description 47
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 239000000651 prodrug Substances 0.000 claims abstract description 41
- 229940002612 prodrug Drugs 0.000 claims abstract description 41
- 239000012453 solvate Substances 0.000 claims abstract description 40
- 239000013078 crystal Substances 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- -1 nitro, carboxy, cyano, amino Chemical group 0.000 claims description 72
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 67
- 125000003545 alkoxy group Chemical group 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 15
- 125000004043 oxo group Chemical class O=* 0.000 claims description 15
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 125000004663 dialkyl amino group Chemical class 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical class 0.000 claims description 11
- 125000003342 alkenyl group Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 4
- 125000002252 acyl group Chemical class 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 42
- 239000000203 mixture Substances 0.000 abstract description 21
- 230000001404 mediated effect Effects 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 73
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 58
- 238000006243 chemical reaction Methods 0.000 description 57
- 239000002904 solvent Chemical class 0.000 description 36
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 35
- 230000002829 reductive effect Effects 0.000 description 35
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 20
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 19
- 238000004440 column chromatography Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 16
- 239000012312 sodium hydride Substances 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 238000010791 quenching Methods 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- OMKFERUUJLBAHC-UHFFFAOYSA-N NC1=CC=C2C3(CNC(C2=C1)=O)CC3 Chemical compound NC1=CC=C2C3(CNC(C2=C1)=O)CC3 OMKFERUUJLBAHC-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- YESNXYJGTJATLQ-UHFFFAOYSA-N NC1=CC=C2C3(CNC(C2=C1)=O)CCC3 Chemical compound NC1=CC=C2C3(CNC(C2=C1)=O)CCC3 YESNXYJGTJATLQ-UHFFFAOYSA-N 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 239000011535 reaction buffer Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 4
- OBDIDGKANKNXDV-GFCCVEGCSA-N 2-[[(2r)-oxiran-2-yl]methyl]-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC=CC=C2CN1C[C@@H]1CO1 OBDIDGKANKNXDV-GFCCVEGCSA-N 0.000 description 4
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 102000006947 Histones Human genes 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 208000000172 Medulloblastoma Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 4
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 3
- CJAVMZHRUSSJST-XMMPIXPASA-N C1COCCC1C(=O)NC2=CC3=C(C=C2)C4(CC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O Chemical compound C1COCCC1C(=O)NC2=CC3=C(C=C2)C4(CC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O CJAVMZHRUSSJST-XMMPIXPASA-N 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- ZXEKHINEFCXRGU-UHFFFAOYSA-N O=C1NCC2(C3=CC=C(C=C13)NC(C1=CC=CC=C1)=O)CC2 Chemical compound O=C1NCC2(C3=CC=C(C=C13)NC(C1=CC=CC=C1)=O)CC2 ZXEKHINEFCXRGU-UHFFFAOYSA-N 0.000 description 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 3
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- IROMFZYAEWDUIL-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C2C3(CNC(C2=C1)=O)CCC3 Chemical compound [N+](=O)([O-])C1=CC=C2C3(CNC(C2=C1)=O)CCC3 IROMFZYAEWDUIL-UHFFFAOYSA-N 0.000 description 3
- 229960001570 ademetionine Drugs 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 208000025750 heavy chain disease Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 208000003476 primary myelofibrosis Diseases 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- WOWAAVPJNOLUDA-UHFFFAOYSA-N 1-(cyclopropanecarbonyl)piperidin-4-one Chemical compound C1CC(=O)CCN1C(=O)C1CC1 WOWAAVPJNOLUDA-UHFFFAOYSA-N 0.000 description 2
- NNFOVLFUGLWWCL-UHFFFAOYSA-N 1-acetylpiperidin-4-one Chemical compound CC(=O)N1CCC(=O)CC1 NNFOVLFUGLWWCL-UHFFFAOYSA-N 0.000 description 2
- WFCLWJHOKCQYOQ-UHFFFAOYSA-N 1-acetylpiperidine-4-carboxylic acid Chemical compound CC(=O)N1CCC(C(O)=O)CC1 WFCLWJHOKCQYOQ-UHFFFAOYSA-N 0.000 description 2
- UPPPWUOZCSMDTR-UHFFFAOYSA-N 1-methyl-pyrazole-4-carboxylic acid Chemical compound CN1C=C(C(O)=O)C=N1 UPPPWUOZCSMDTR-UHFFFAOYSA-N 0.000 description 2
- PHLZCDRZIRSOJU-XMMPIXPASA-N 2-[(2R)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-7-(piperidin-4-ylamino)spiro[3H-isoquinoline-4,1'-cyclopropane]-1-one Chemical compound C1CNCCC1NC2=CC3=C(C=C2)C4(CC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O PHLZCDRZIRSOJU-XMMPIXPASA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- IRYXSELPLSAVII-AREMUKBSSA-N C(C)(=O)N1CCC(CC1)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CC3 Chemical compound C(C)(=O)N1CCC(CC1)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CC3 IRYXSELPLSAVII-AREMUKBSSA-N 0.000 description 2
- VNDRXHMLWXEKRR-MUUNZHRXSA-N C(C)(=O)N1CCC(CC1)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CCCC3 Chemical compound C(C)(=O)N1CCC(CC1)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CCCC3 VNDRXHMLWXEKRR-MUUNZHRXSA-N 0.000 description 2
- JQWLMUBIQOZJHL-GDLZYMKVSA-N C1CCC2(C1)CN(C(=O)C3=C2C=CC(=C3)NC4CCN(CC4)C(=O)C5CC5)C[C@@H](CN6CCC7=CC=CC=C7C6)O Chemical compound C1CCC2(C1)CN(C(=O)C3=C2C=CC(=C3)NC4CCN(CC4)C(=O)C5CC5)C[C@@H](CN6CCC7=CC=CC=C7C6)O JQWLMUBIQOZJHL-GDLZYMKVSA-N 0.000 description 2
- PAVNJZBDTZTDRC-HHHXNRCGSA-N CC(=O)N1CCC(CC1)NC2=CC3=C(C=C2)C4(CCC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O Chemical compound CC(=O)N1CCC(CC1)NC2=CC3=C(C=C2)C4(CCC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O PAVNJZBDTZTDRC-HHHXNRCGSA-N 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- ZYLAPCHDEWGXGS-HSZRJFAPSA-N CN1C=C(C=N1)C(=O)NC2=CC3=C(C=C2)C4(CC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O Chemical compound CN1C=C(C=N1)C(=O)NC2=CC3=C(C=C2)C4(CC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O ZYLAPCHDEWGXGS-HSZRJFAPSA-N 0.000 description 2
- PEWLSNMMANEVOE-XMMPIXPASA-N CN1C=C(C=N1)C(=O)NC2=CC3=C(C=C2)C4(CCC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O Chemical compound CN1C=C(C=N1)C(=O)NC2=CC3=C(C=C2)C4(CCC4)CN(C3=O)C[C@@H](CN5CCC6=CC=CC=C6C5)O PEWLSNMMANEVOE-XMMPIXPASA-N 0.000 description 2
- HYWHDIKCPPEWJH-UHFFFAOYSA-N COC(=O)c1ccccc1C1(CC1)C#N Chemical compound COC(=O)c1ccccc1C1(CC1)C#N HYWHDIKCPPEWJH-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 101000611943 Homo sapiens Programmed cell death protein 4 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100040992 Programmed cell death protein 4 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 102000004394 Ribosomal protein S10 Human genes 0.000 description 2
- 108090000928 Ribosomal protein S10 Proteins 0.000 description 2
- 208000006938 Schwannomatosis Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- XVCZXLQZWJDXIO-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C2C3(CNC(C2=C1)=O)CC3 Chemical compound [N+](=O)([O-])C1=CC=C2C3(CNC(C2=C1)=O)CC3 XVCZXLQZWJDXIO-UHFFFAOYSA-N 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000006217 arginine-methylation Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 208000034737 hemoglobinopathy Diseases 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- FNSQENYXHQMRRY-UHFFFAOYSA-N methyl 2-(1-cyanocyclobutyl)benzoate Chemical compound C(#N)C1(CCC1)C1=C(C(=O)OC)C=CC=C1 FNSQENYXHQMRRY-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 201000009494 neurilemmomatosis Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 2
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- JOQRTJVKPMLHSJ-UHFFFAOYSA-N spiro[2,3-dihydroisoquinoline-4,1'-cyclobutane]-1-one Chemical compound C12=CC=CC=C2C(=O)NCC21CCC2 JOQRTJVKPMLHSJ-UHFFFAOYSA-N 0.000 description 2
- GEYULTDGKVFWAO-UHFFFAOYSA-N spiro[2,3-dihydroisoquinoline-4,1'-cyclopropane]-1-one Chemical compound C12=CC=CC=C2C(=O)NCC21CC2 GEYULTDGKVFWAO-UHFFFAOYSA-N 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 0 *Ic1ncc(C2(CCCCC2)CN(C[C@@](CN(CC2)Cc3c2cccc3)O)C2=O)c2c1 Chemical compound *Ic1ncc(C2(CCCCC2)CN(C[C@@](CN(CC2)Cc3c2cccc3)O)C2=O)c2c1 0.000 description 1
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical group C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical group BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- IJBXVKITOJFLBF-UHFFFAOYSA-N 1-azaspiro[2.3]hexane Chemical group C1NC11CCC1 IJBXVKITOJFLBF-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- AGXBHBJDSLZGAP-UHFFFAOYSA-N 2-(cyanomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CC#N AGXBHBJDSLZGAP-UHFFFAOYSA-N 0.000 description 1
- OBDIDGKANKNXDV-UHFFFAOYSA-N 2-(oxiran-2-ylmethyl)-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC=CC=C2CN1CC1CO1 OBDIDGKANKNXDV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- HUPNQNOWXCVQSW-UHFFFAOYSA-N 2h-pyran-4-carboxamide Chemical compound NC(=O)C1=CCOC=C1 HUPNQNOWXCVQSW-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- LIOJYBPXTAIBMQ-AREMUKBSSA-N C(C)(=O)N1CCC(CC1)C(=O)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CC3 Chemical compound C(C)(=O)N1CCC(CC1)C(=O)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CC3 LIOJYBPXTAIBMQ-AREMUKBSSA-N 0.000 description 1
- IWXAXHIQKHUHFY-HHHXNRCGSA-N C(C)(=O)N1CCC(CC1)C(=O)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CCC3 Chemical compound C(C)(=O)N1CCC(CC1)C(=O)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CCC3 IWXAXHIQKHUHFY-HHHXNRCGSA-N 0.000 description 1
- SSUMWNDITFRQBG-UHFFFAOYSA-N C(C)(=O)N1CCC(CC1)C(=O)NC1=CC=C2C3(CNC(C2=C1)=O)CC3 Chemical compound C(C)(=O)N1CCC(CC1)C(=O)NC1=CC=C2C3(CNC(C2=C1)=O)CC3 SSUMWNDITFRQBG-UHFFFAOYSA-N 0.000 description 1
- FFAOFUUYPVIMAQ-HHHXNRCGSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CC3 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)NC1=CC=C2C3(CN(C(C2=C1)=O)C[C@@H](CN1CC2=CC=CC=C2CC1)O)CC3 FFAOFUUYPVIMAQ-HHHXNRCGSA-N 0.000 description 1
- KHQIGKQTJJKSQN-UHFFFAOYSA-N C1(CC1)C(=O)N1CCC(CC1)NC1=CC=C2C3(CNC(C2=C1)=O)CCCC3 Chemical compound C1(CC1)C(=O)N1CCC(CC1)NC1=CC=C2C3(CNC(C2=C1)=O)CCCC3 KHQIGKQTJJKSQN-UHFFFAOYSA-N 0.000 description 1
- HRUVPCQQYMKVIX-XMMPIXPASA-N C1N(CCC2=CC=CC=C12)C[C@H](CN1C(C2=CC(=CC=C2C2(C1)CC2)NS(=O)(=O)C2=CC=CC=C2)=O)O Chemical compound C1N(CCC2=CC=CC=C12)C[C@H](CN1C(C2=CC(=CC=C2C2(C1)CC2)NS(=O)(=O)C2=CC=CC=C2)=O)O HRUVPCQQYMKVIX-XMMPIXPASA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- XNLCDUUXMWAXMY-UHFFFAOYSA-N C[n]1ncc(C(Nc2cc(C(NCC34CC3)=O)c4cc2)=O)c1 Chemical compound C[n]1ncc(C(Nc2cc(C(NCC34CC3)=O)c4cc2)=O)c1 XNLCDUUXMWAXMY-UHFFFAOYSA-N 0.000 description 1
- 101100216105 Caenorhabditis elegans prmt-1 gene Proteins 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000006453 Class 3 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 1
- 108010044214 Class 3 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010052778 Golgi Matrix Proteins Proteins 0.000 description 1
- 102000018884 Golgi Matrix Proteins Human genes 0.000 description 1
- 101000796144 Homo sapiens Protein arginine N-methyltransferase 9 Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 206010073365 Intraductal papillary mucinous carcinoma of pancreas Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- DZPCLDXDJRRWBX-UHFFFAOYSA-N O=C1NCC2(C3=CC=C(C=C13)NC(=O)C1CCOCC1)CC2 Chemical compound O=C1NCC2(C3=CC=C(C=C13)NC(=O)C1CCOCC1)CC2 DZPCLDXDJRRWBX-UHFFFAOYSA-N 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 208000017459 Paget disease of the penis Diseases 0.000 description 1
- 208000025610 Paget disease of the vulva Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102100031369 Protein arginine N-methyltransferase 9 Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 101710138750 Transcription factor E2F1 Proteins 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- FUASJQSBFUVWJQ-UHFFFAOYSA-N [N].NC(N)=N Chemical compound [N].NC(N)=N FUASJQSBFUVWJQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010059394 acanthoma Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 208000025751 alpha chain disease Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- MSXKFSFICXVOAJ-UHFFFAOYSA-N cyclopentylsulfanylcyclopentane Chemical compound C1CCCC1SC1CCCC1 MSXKFSFICXVOAJ-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 208000004313 familial eosinophilia Diseases 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- CMADSXVGXNLKHA-UHFFFAOYSA-N methyl 2-(cyanomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CC#N CMADSXVGXNLKHA-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000026114 mu chain disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000024305 myofibroblastoma Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000004754 pancreatic intraductal papillary-mucinous neoplasm Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000014956 scrotum Paget disease Diseases 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 201000008753 synovium neoplasm Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003666 tauryl group Chemical group [H]N([H])C([H])([H])C([H])([H])S(*)(=O)=O 0.000 description 1
- XTDXZSGSIMLARD-UHFFFAOYSA-N tert-butyl 2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC=C1 XTDXZSGSIMLARD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Definitions
- the present invention belongs to the field of medicinal chemistry, and specifically relates to tricyclic compounds or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof as PRMT5 inhibitors, their preparation methods and pharmaceutical combinations containing these compounds And the use of these compounds or compositions for the treatment of PRMT5-mediated diseases.
- DNA modification plays a central role in triggering gene expression programs at different stages of cell growth and development.
- Arginine methylation plays an important role in cell processes, including signal transduction, transcription, RNA processing, DNA recombination and repair .
- Protein arginine methyltransferases catalyze the methylation of specific arginine residues by transferring methyl groups from S-adenosylmethionine (SAM) to the guanidine nitrogen of arginine.
- SAM S-adenosylmethionine
- the different arginine methylation methods can divide PRMTs into three categories: Type I (PRMT 1, 2, 3, 4, 6 and 8) catalyzes monomethylation and asymmetric dimethylation, and type II (PRMT5). And PRMT9) catalyze monomethylation and symmetric dimethylation, while type III (PRMT7) only performs monomethylation.
- PRMT5 specifically binds to methyltransferase complex protein 50 (MEP50), which can symmetrically methylate histones H3 and H4, and regulate the transcription of specific target genomes.
- MEP50 methyltransferase complex protein 50
- PRMT5 catalyzed histone H3 arginine 8 (R8) and H4R3 symmetric dimethylation has been shown to inhibit the expression of several tumor suppressor genes, such as tumor suppressor gene 7 (ST7), retinoblastoma (RB) tumor suppressor genes Family and receptor type O protein tyrosine phosphatase (PTPROt).
- T7 tumor suppressor gene 7
- RB retinoblastoma
- PTPROt Family and receptor type O protein tyrosine phosphatase
- PRMT5 can also methylate several important transcription factors, making it play an important role in cell regulation.
- PRMT5 can methylate p53 and change its DNA binding activity, thereby triggering changes in the gene expression program controlled by p53.
- PRMT5 has also been shown to methylate N-MYC and change its protein stability and enhance its oncogenic activity in neuroblastoma.
- PRMT5 can also directly methylate transcription factors, including E2F-1 and NF- ⁇ B/p65, and induce the expression of its target genes.
- PRMT5 can not only modify nuclear transcription factors, but also methylate cytoplasmic proteins such as golgin and ribosomal protein S10 (RPS10). Therefore, in addition to its ability to directly regulate its own target genes, PRMT5 can also indirectly affect global gene expression through symmetric methylation of key transcription factors, thereby affecting cell growth, proliferation and differentiation.
- PRMT5 is overexpressed in different types and aggressive cancers, including B-cell and T-cell lymphoma, metastatic melanoma, neuroblastoma and glioblastoma, germ cell tumors, ovarian cancer, Nasopharyngeal cancer, breast cancer, colorectal cancer and gastric cancer.
- Current research shows that PRMT5 plays an important role in controlling cell growth and proliferation, and its overexpression promotes cell transformation.
- PRMT5 The enhanced expression of PRMT5 in cancer cells is related to the transcriptional silencing of its target tumor suppressor genes.
- PRMT5 can promote the growth of cancer cells by methylation of the promoter histones H3R8 and H4R3 and by modifying specific arginine residues of key transcription factors including E2F1 and NF-kB/p65 to cause global chromatin changes.
- PRMT5 also interacts with programmed cell death 4 (PDCD4), causing it to become methylated at R110 and lose its tumor suppressor activity in MCF-7 cells.
- PDCD4 programmed cell death 4
- the overexpression of PRMT5 may make it interact with growth promoting proteins and tumor suppressor proteins to facilitate the growth, survival and metastasis of cancer cells.
- PRMT5 inhibitors have a clear mechanism in the treatment of tumors and other related diseases, and have great potential to become a new treatment method in the field of tumor treatment. Therefore, it is necessary to develop safer and more effective PRMT5 inhibitors to meet clinical needs. demand.
- An object of the present invention is to provide a class of compounds with PRMT5 inhibitory activity represented by general formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof,
- Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl, and the aryl, heteroaryl, cycloalkyl and heterocyclic group may be one or more selected from halogen, hydroxy, alkyl, Haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, alkylsulfonyl, amino Substitution of acyl, alkylaminoacyl, dialkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and oxo groups;
- Cy is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocyclyl.
- the aryl, heteroaryl, cycloalkyl, and heterocyclic group may be one or more selected from halogen, hydroxy, alkyl, and halogenated alkyl.
- hydroxyalkyl alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, alkylsulfonyl, aminoacyl , Alkylamino acyl, dialkylamino, alkenyl, alkynyl, haloalkyl acyl, hydroxyalkyl acyl, cycloalkyl acyl, heterocyclyl acyl, cycloalkyl, heterocyclic, aryl, heteroaryl And oxo group substitution;
- R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, Cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl and dialkylamino;
- R 5 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkylacyl, aminoacyl and alkylaminoacyl;
- X 1 , X 2 , and X 3 are each independently selected from N and C (R 6 ), wherein R 6 is selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, Hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, and cycloalkyl; and
- L is selected from -NH-, -S-, -O-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -S(O ) 2 NH-, -NHS(O) 2 -, -C(O)- and -NHC(O)NH-.
- Another object of the present invention is to provide a method for preparing the compound of general formula (I) of the present invention or its isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug.
- Another object of the present invention is to provide a composition
- a composition comprising the compound of the general formula (I) of the present invention or its isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs and a pharmaceutically acceptable carrier, and The compound of the general formula (I) of the present invention or its isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs and a combination of another or more drugs.
- Another object of the present invention is to provide a method for treating PRMT5-mediated diseases with the compound of general formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof of the present invention, and the present invention Application of the compound of general formula (I) or its isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs in the preparation of medicines for treating PRMT5-mediated diseases.
- the present invention provides a compound represented by general formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof,
- Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl, and the aryl, heteroaryl, cycloalkyl and heterocyclic group may be one or more selected from halogen, hydroxy, alkyl, Haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, alkylsulfonyl, amino Substitution of acyl, alkylaminoacyl, dialkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and oxo groups;
- Cy is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocyclyl.
- the aryl, heteroaryl, cycloalkyl, and heterocyclic group may be one or more selected from halogen, hydroxy, alkyl, and halogenated alkyl.
- R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, Cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl and dialkylamino;
- R 5 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkylacyl, aminoacyl and alkylaminoacyl;
- X 1 , X 2 , and X 3 are each independently selected from N and C (R 6 ), wherein R 6 is selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, Hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, and cycloalkyl; and
- L is selected from -NH-, -S-, -O-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -S(O ) 2 NH-, -NHS(O) 2 -, -C(O)- and -NHC(O)NH-.
- the compound of the present invention is a compound of general formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, wherein:
- Ring A is selected from C 6-12 aryl, 5-12 membered heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic group
- the C 6-12 aryl, 5-12 membered heteroaryl Group, C 3-12 cycloalkyl and 3-12 membered heterocyclic group can be selected by one or more selected from halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxy C 1-6 Alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkyl acylamino, C 1-6 alkyl acyl, C 1-6 alkylsulfonyl, amino acyl, C 1-6 alkylamino acyl, bis C 1-6 alkylamino, C 2-10 Alkenyl, C 2-10 alkynyl, C 3-12 cycl
- ring A is selected from C 6-10 aryl, 5-10 membered heteroaryl, C 3-10 cycloalkyl and 3-10 membered heterocyclic group, the C 6-10 aryl, 5-
- the 10-membered heteroaryl group, C 3-10 cycloalkyl group and 3-10 membered heterocyclic group may be one or more selected from halogen, hydroxy, C 1-3 alkyl, halogenated C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxy, cyano, amino, mono C 1-3 alkane amino, acylamino C 1-3 alkyl, C 1-3 alkyl group, C 1-3 alkyl sulfonyl, amino group, C 1-3 alkylamino group, a bis C 1-3 alkyl group, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cyclo
- ring A is selected from C 6-8 aryl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, 3-6 membered azaheterocyclyl, 3-6 membered oxoheterocyclyl, 3-6 membered sulfur heterocyclic group, the C 6-8 aryl group, 5-6 membered heteroaryl group, C 3-6 cycloalkyl group, 3-6 membered azacyclic group, 3-6 membered oxygen heterocyclic group Group, 3-6 membered sulfur heterocyclic group can be selected by one or more selected from halogen, hydroxy, C 1-3 alkyl, halo C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 Alkoxy, halogenated C 1-3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxyl, cyano, amino, mono C 1-3 alkylamino, C 1-3 alkyl acylamino , C 1-3 alkyl acyl,
- ring A is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, aziridine Group, azetidinyl, tetrahydropyrrolyl, dihydropyrrolyl, pyrrolyl, piperidinyl, tetrahydropyridyl, dihydropyridyl, pyridyl, propylene oxide, oxetanyl , Tetrahydrofuranyl, dihydrofuranyl, furanyl, tetrahydropyranyl, dihydropyranyl, pyranyl, sulfiethane, sulfide cyclobutanyl, tetrahydrothienyl, dihydrothienyl, Thienyl, cyclopentanyl
- the compound of the present invention is a compound of general formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, wherein:
- Cy is selected from C 6-12 aryl, 5-12 membered heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic group
- the C 6-12 aryl, 5-12 membered heteroaryl , C 3-12 cycloalkyl and 3-12 membered heterocyclic group can be selected by one or more selected from halogen, hydroxy, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkane Group, C 1-6 alkoxy, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1 -6 alkyl acylamino, C 1-6 alkyl acyl, C 1-6 alkyl sulfonyl, amino acyl, C 1-6 alkyl amino acyl, double C 1-6 alkyl amino, C 2-10 alkene Group, C 2-10 alkynyl, halogenated
- Cy is selected from C 6-10 aryl, 5-10 membered heteroaryl, C 3-10 cycloalkyl and 3-10 membered heterocyclic group, the C 6-10 aryl, 5-10
- One or more membered heteroaryl groups, C 3-10 cycloalkyl groups and 3-10 membered heterocyclic groups may be selected from halogen, hydroxy, C 1-3 alkyl, halogenated C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxy, cyano, amino, mono C 1-3 alkyl Amino, C 1-3 alkyl acylamino, C 1-3 alkyl acyl, C 1-3 alkyl sulfonyl, amino acyl, C 1-3 alkyl amino acyl, bis C 1-3 alkyl amino, C 2-6 alkenyl, C 2-6 alkynyl, halogenated
- Cy is selected from phenyl, 5-6 membered heteroaryl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 3-6 membered heterocyclyl
- the phenyl, 5-6 Member heteroaryl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 3-6 membered heterocyclic group can be selected by one or more selected from halogen, hydroxy, C 1-3 alkyl, halogenated C 1 -3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxy, cyano, amino, Mono-C 1-3 alkylamino, C 1-3 alkyl acylamino, C 1-3 alkyl acyl, C 1-3 alkylsulfonyl, amino acyl, C 1-3 alkylamino
- the compound of the present invention is a compound of general formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, wherein:
- R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 Alkoxy, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxyl, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkyl acylamino , C 1-6 alkyl acyl, amino acyl, C 1-6 alkyl amino acyl and double C 1-6 alkyl amino;
- R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, halogen, hydroxyl, C 1-3 alkyl, halogenated C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkoxy, hydroxyl C 1-3 alkoxy, nitro, carboxyl, cyano, amino, mono C 1-3 alkylamino, C 1-3 Alkyl acylamino, C 1-3 alkyl acyl, amino acyl, C 1-3 alkylamino acyl and bis C 1-3 alkylamino;
- R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, halogen, hydroxyl, methyl, ethyl, propyl, isopropyl, halogenated C 1-3 alkyl, hydroxyl C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxy, cyano, amino, mono C 1-3 alkane Alkylamino, C 1-3 alkyl acylamino, C 1-3 alkyl acyl, amino acyl, C 1-3 alkylamino acyl and bis C 1-3 alkylamino.
- the compound of the present invention is a compound of general formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, wherein:
- R 5 is selected from hydrogen, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkyl acyl, amino acyl, C 1-6 alkylamino acyl;
- R 5 is selected from hydrogen, C 1-3 alkyl, halogenated C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkyl acyl, amino acyl, C 1-3 alkane Aminoacyl;
- R 5 is selected from hydrogen, methyl, ethyl, propyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, methylacyl, ethylacyl, propylacyl, aminoacyl, methyl Aminoacyl, ethylaminoacyl and propylaminoacyl.
- the compound of the present invention is a compound of general formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, wherein:
- R 6 is selected from hydrogen, halogen, hydroxy, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy Group, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkyl acylamino, C 1-6 alkyl acyl, amino acyl, C 1-6 alkylaminoacyl, bis-C 1-6 alkylamino and C 3-12 cycloalkyl;
- R 6 is selected from hydrogen, halogen, hydroxy, C 1-3 alkyl, halogenated C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1 -3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxy, cyano, amino, mono C 1-3 alkylamino, C 1-3 alkyl acylamino, C 1-3 alkyl acyl , Aminoacyl, C 1-3 alkylamino acyl, double C 1-3 alkylamino and C 3-8 cycloalkyl;
- R 6 is selected from hydrogen, halogen, hydroxy, methyl, ethyl, propyl, isopropyl, halogenated C 1-3 alkyl, hydroxy C 1-3 alkyl, C 1-3 alkane Oxy, halogenated C 1-3 alkoxy, hydroxy C 1-3 alkoxy, nitro, carboxy, cyano, amino, mono C 1-3 alkylamino, C 1-3 alkyl acylamino, C 1-3 alkyl acyl, amino acyl, C 1-3 alkyl amino acyl, bis C 1-3 alkylamino and C 3-8 cycloalkyl.
- the present invention provides a compound of general formula (Ia) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof,
- Cy, L and ring A have the definitions described in the general formula (I) above.
- the present invention provides a compound of general formula (Ib) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof,
- Cy, L and ring A have the definitions described in the general formula (I) above.
- the present invention provides a compound of general formula (Ic) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof,
- Cy, L and ring A have the definitions described in the general formula (I) above.
- the present invention provides a compound of general formula (Id) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof,
- Cy, L and ring A have the definitions described in the general formula (I) above.
- the compound of the present invention is a compound of general formula (I), (Ia), (Ib), (Ic) or (Id) or its isomers, pharmaceutically acceptable salts, solvents Compounds, crystals or prodrugs, of which:
- the present invention provides the following specific compounds or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof:
- the present invention provides a method for preparing the compound of general formula (I) of the present invention, which includes the step of reacting the compound of formula 1 and the compound of formula 2:
- R 1 , R 2 , R 3 , R 4 , R 5 , Cy, L, X 1 , X 2 , X 3 , and ring A have the definitions described in the general formula (I), and the compound of formula 1 and formula 2
- the compound of is a commercially available compound or can be synthesized by other technical means commonly used by those skilled in the art.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof.
- the present invention provides the compound of the present invention or its isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs and the compounds of the present invention or its isomers, pharmaceutically acceptable Pharmaceutical compositions of salts, solvates, crystals or prodrugs, said compounds or pharmaceutical compositions are used to treat PRMT5-mediated diseases.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the present invention or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, and a pharmaceutically acceptable carrier.
- the compound of the present invention or its isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs can be mixed with pharmaceutically acceptable carriers, diluents or excipients to prepare pharmaceutical preparations suitable for oral administration or Parenteral administration.
- Administration methods include, but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal and oral routes.
- the preparation can be administered by any route, for example, by infusion or bolus injection, by the route of absorption through the epithelium or skin mucosa (such as oral mucosa or rectum, etc.). Administration can be systemic or local.
- preparations for oral administration include solid or liquid dosage forms, specifically, tablets, pills, granules, powders, capsules, syrups, emulsions, suspensions, and the like.
- the preparation can be prepared by a method known in the art, and contains a carrier, diluent or excipient conventionally used in the field of pharmaceutical preparations.
- the present invention provides a compound represented by formula (I), (Ia), (Ib), (Ic) or (Id) or its isomers, pharmaceutically acceptable salts, solvates, crystals Or a prodrug, or a pharmaceutical composition containing the same for the method of treating PRMT5-mediated diseases and the use in the preparation of a medicine for treating PRMT5-mediated diseases.
- the present invention provides a compound represented by formula (I), (Ia), (Ib), (Ic) or (Id) of the present invention or an isomer, pharmaceutically acceptable salt thereof, Solvates, crystals or prodrugs, or pharmaceutical compositions containing them are used to treat PRMT5-mediated diseases and their use in the preparation of drugs for the treatment of PRMT5-mediated diseases, wherein the PRMT5-mediated diseases include But not limited to: proliferative diseases, metabolic diseases or blood diseases.
- the PRMT5-mediated disease of the present invention is cancer.
- PRMT5-mediated diseases of the present invention include but are not limited to: acoustic neuroma, adenocarcinoma, adrenal carcinoma, anal cancer, angiosarcoma (eg, lymphangiosarcoma, lymphatic endothelial sarcoma, angiosarcoma) , Accessory cancer, benign monoclonal gammopathy, bile cancer (for example, cholangiocarcinoma), bladder cancer, breast cancer (for example, breast adenocarcinoma, breast papillary cancer, breast cancer, breast medullary cancer, triple negative breast cancer ), brain cancer (for example, meningioma; glioma, such as astrocytoma, oligodendroglioma; medulloblastoma), bronchial carcinoma, carcinoid tumor, cervical cancer (for example, cervical adenocarcinoma) , Choriocarcinoma, chordoma, craniopharyn
- Gastrointestinal pancreatic neuroendocrine tumors GEP-NET
- carcinoid tumors carcinoid tumors
- osteosarcoma ovarian cancer
- ovarian cancer e.g., cystadenocarcinoma, ovarian embryonic carcinoma, ovarian adenocarcinoma, ovarian clear cell carcinoma, ovarian serous cystadenocarcinoma ,
- papillary adenocarcinoma pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary myxoma (IPMN), islet cell tumor)
- penile cancer e.g., Paget's disease of the penis and scrotum
- Pineal tumor e.g., Primary neuroectodermal tumor (PNT)
- prostate cancer for example, prostate adenocarcinoma
- rectal cancer rhabdomyosarcoma
- salivary duct cancer for example, squam
- the PRMT5-mediated diseases of the present invention include metabolic disorders such as diabetes or obesity.
- the PRMT5-mediated diseases of the present invention include hemoglobinopathies such as sickle cell disease or ⁇ -thalassemia.
- the PRMT5-mediated diseases of the present invention include inflammatory and autoimmune diseases.
- the present invention provides a compound represented by general formula I of the present invention or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, or a pharmaceutical composition containing it for use Method for treating PRMT5-mediated diseases and use in the preparation of drugs for treating PRMT5-mediated diseases, wherein the PRMT5-mediated diseases include but not limited to: breast cancer, esophageal cancer, bladder cancer, lung cancer, hematopoietic system Cancer, lymphoma, medulloblastoma, medulloblastoma, rectal adenocarcinoma, colon cancer, stomach cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, prostate cancer, lung cancer, head and neck squamous cell carcinoma, brain Carcinoma, hepatocellular carcinoma, melanoma, oligodendroglioma, glioblastoma, testicular cancer, ovarian clear cell carcinoma, ovarian serous cystadenocarcino
- hydrogen, carbon and oxygen in the compounds of the present invention include all their isotopes.
- Isotopes should be understood to include those atoms having the same atomic number but different mass numbers.
- hydrogen isotopes include protium, tritium, and deuterium
- carbon isotopes include 12 C, 13 C, and 14 C
- oxygen isotopes include 16 O and 18 O.
- “Isomers” in the present invention refer to molecules with the same atomic composition and connection mode but different three-dimensional arrangements, including but not limited to diastereomers, enantiomers, cis-trans isomers, and their Mixtures, such as racemic mixtures.
- Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of plane-polarized light.
- the prefixes D, L or R, S are used to indicate the absolute configuration of the molecular chiral center.
- the prefixes D, L or (+), (-) are used to name the symbols of the plane-polarized light rotation of the compound.
- (-) or L means the compound is levorotatory, and the prefix (+) or D means the compound is dextrorotatory.
- the chemical structures of these stereoisomers are the same, but their stereostructures are different.
- a specific stereoisomer may be an enantiomer, and a mixture of isomers is usually called an enantiomeric mixture.
- a 50:50 mixture of enantiomers is called a racemic mixture or a racemate, which may result in no stereoselectivity or stereospecificity during chemical reactions.
- racemic mixture and “racemate” refer to an equimolar mixture of two enantiomers, lacking optical activity.
- the compound of the present invention can be one of the possible isomers or a mixture of them, such as racemates and diastereoisomer mixtures (depending on the number of asymmetric carbon atoms) The form exists.
- Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, and diastereomers based on differences in the physical and chemical properties of the components, for example, by chromatography Method and/or fractional crystallization method.
- halogen in the present invention means fluorine, chlorine, bromine, and iodine.
- halo in the present invention refers to substitution by fluorine, chlorine, bromine or iodine.
- alkyl in the present invention refers to a linear or branched saturated aliphatic hydrocarbon group, preferably a linear or branched group containing 1 to 6 carbon atoms, and more preferably a linear or branched group containing 1 to 3 carbon atoms
- Chain groups non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethyl Propyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, etc.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be at any available point of attachment.
- the "sulfonyl group" in the present invention means -S(O) 2 -.
- the "sulfonamide group" in the present invention means -S(O) 2 NH-.
- haloalkyl in the present invention refers to an alkyl group substituted with at least one halogen.
- hydroxyalkyl in the present invention refers to an alkyl group substituted with at least one hydroxy group.
- Alkoxy in the present invention refers to -O-alkyl.
- alkoxy groups include: methoxy, ethoxy, propoxy, n-propoxy, isopropoxy, isobutoxy, sec-butoxy and the like.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent may be at any available point of attachment.
- cycloalkyl in the present invention refers to a cyclic saturated hydrocarbon group. Suitable cycloalkyl groups may be substituted or unsubstituted monocyclic, bicyclic or tricyclic saturated hydrocarbon groups with 3-12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- heterocyclic group refers to a 3- to 12-membered non-aromatic group having 1 to 4 ring heteroatoms (wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon) Groups of ring systems ("3-12 membered heterocyclyl").
- heterocyclyl groups containing one or more nitrogen atoms the point of attachment may be a carbon or nitrogen atom, as long as the valence permits.
- Heterocyclyl groups can either be monocyclic (“monocyclic heterocyclyl”) or fused, bridged or spiro ring systems (e.g.
- bicyclic systems also known as "bicyclic heterocyclyl"
- Suitable heterocyclic groups include but are not limited to piperidinyl, azetidinyl, aziridinyl, tetrahydropyrrolyl, piperazinyl, dihydroquinazolinyl, oxepanyl, oxa Cyclobutyl, tetrahydrofuranyl, tetrahydropyranyl, Wait.
- Each instance of the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent may be at any available point of attachment.
- aryl refers to an aromatic system that can contain a single ring or a fused polycyclic ring, preferably a single ring or a fused bicyclic aromatic system, which contains 6 to 12 carbon atoms, preferably about 6 to about 10 carbon atoms.
- Suitable aryl groups include, but are not limited to, phenyl, naphthyl, anthryl, fluorenyl, indanyl.
- the aryl group may be optionally substituted or unsubstituted, and when substituted, the substituent may be at any available point of attachment.
- heteroaryl group in the present invention refers to an aryl group in which at least one carbon atom is replaced by a heteroatom, preferably composed of 5-12 atoms (5-12 membered heteroaryl), and more preferably composed of 5-10 atoms (5-10 membered heteroaryl), the heteroatoms are O, S, N.
- heteroaryl groups include, but are not limited to, imidazolyl, pyrrolyl, furyl, thienyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, Tetrazolyl, indolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, isoindolyl, benzopyrazolyl, benzimidazolyl, benzofuranyl, benzopyridine Pyryl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, Quinoxalinyl, benzoxazinyl, benzothiazinyl
- the “pharmaceutically acceptable salt” of the present invention refers to the salt of the compound of the present invention. Such salt is safe and effective when used in mammals, and has due biological activity.
- solvate in the present invention refers to a complex formed by the combination of a solute (such as an active compound, a salt of an active compound) and a solvent (such as water) in a conventional sense.
- the solvent refers to a solvent known or easily determined by those skilled in the art. If it is water, the solvate is usually referred to as a hydrate, such as hemihydrate, monohydrate, dihydrate, trihydrate, or alternative amounts thereof.
- the in vivo effects of the compound of formula (I) can be partly exerted by one or more metabolites formed in the body of the human or animal after the compound of formula (I) is administered. As described above, the in vivo effects of the compound of formula (I) can also be exerted through the metabolism of precursor compounds ("prodrugs").
- the "prodrug” of the present invention refers to a compound that is converted into a compound of the invention by reaction with enzymes, gastric acid, etc. under physiological conditions in an organism, that is, a compound that is converted into a compound of the invention by enzyme oxidation, reduction, hydrolysis, etc. /Or a compound or the like that is converted into a compound of the invention by a hydrolysis reaction of gastric acid or the like.
- the "crystalline" in the present invention refers to a solid whose internal structure is formed by repeating constituent atoms (or groups thereof) regularly in three dimensions, which is different from an amorphous solid that does not have such a regular internal structure.
- the "pharmaceutical composition” of the present invention refers to containing any of the compounds of the present invention, including corresponding isomers, prodrugs, solvates, pharmaceutically acceptable salts or chemically protected forms thereof, and a Or a mixture of multiple pharmaceutically acceptable carriers and/or another one or more drugs.
- the purpose of the pharmaceutical composition is to facilitate the administration of the compound to the organism.
- the composition is generally used to prepare drugs for the treatment and/or prevention of diseases mediated by one or more kinases.
- the "pharmaceutically acceptable carrier” in the present invention refers to a carrier that does not cause significant irritation to organisms and does not interfere with the biological activity and properties of the administered compound, and includes all solvents, diluents or other excipients, dispersants, and surface activities. Isotonic agent, thickener or emulsifier, preservative, solid binder, lubricant, etc. Unless any conventional carrier medium is incompatible with the compound of the present invention.
- pharmaceutically acceptable carriers include, but are not limited to, sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, And cellulose and cellulose acetate; malt, gelatin, etc.
- excipient refers to an inert substance added to a pharmaceutical composition to further facilitate the administration of a compound.
- Excipients may include calcium carbonate, calcium phosphate, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oil, and polyethylene glycol.
- the "PRMT5" of the present invention may be any mutant or variant of wild-type PRMT5 or PRMT5, and the mutant or variant of PRMT5 contains one or more mutations (for example, conservative substitutions).
- Step 3 Preparation of 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one
- Step 4 Preparation of 7'-amino-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one
- Step 5 7'-((1-Acetylpiperidin-4-yl)amino)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]- Preparation of 1′-ketone
- Step 6 (R)-7′-((1-Acetylpiperidin-4-yl)amino)-2′-(3-(3,4-dihydroisoquinolin-2(1H)-yl) -2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one
- reaction solution was poured into 200 mL saturated ammonium chloride solution for quenching, extracted with ethyl acetate (100 mL ⁇ 3), the organic phases were combined, dried, the solvent was evaporated under reduced pressure, and the title compound was separated by column chromatography.
- LC-MS m/z: [M+H] + 216.
- Step 3 Preparation of 7'-nitro-2',3'-dihydro-1'H-spiro[cyclobutane-1,4'-isoquinoline]-1'-one
- Step 4 Preparation of 7'-amino-2',3'-dihydro-1'H-spiro[cyclobutane-1,4'-isoquinoline]-1'-one
- Step 6 (R)-7′-((1-Acetylpiperidin-4-yl)amino)-2′-(3-(3,4-dihydroisoquinolin-2(1H)-yl) -2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclobutane-1,4'-isoquinoline]-1'-one
- reaction solution was poured into 30mL saturated ammonium chloride solution for quenching, extracted with dichloromethane (20mL ⁇ 3), combined the organic phases, evaporated the solvent under reduced pressure to obtain the crude product, prepared and separated by prep-HPLC to obtain the title compound .
- the preparation method is similar to the preparation method of Example 1, except that the raw material 1,2-dibromoethane in step 1 is replaced with 1,4-dibromobutane to obtain the title compound.
- 1 H NMR 300MHz, DMSO-d 6 ) ⁇ 7.00-7.40 (m, 6H), 6.75 (d, 1H), 5.59 (d, 1H), 4.72 (brs, 1H), 4.18 (d, 1H), 4.02 (s, 1H), 3.70-3.80 (m, 2H), 3.62 (s, 2H), 3.45-3.51 (m, 2H), 3.30-3.41 (m, 2H), 3.10-3.20 (m, 2H), 2.60-2.80 (m, 5H), 2.30-2.50 (m, 2H), 2.00 (s, 3H), 1.80-1.95 (m, 2H), 1.50-1.80 (m, 7H), 1.10-1.30 (m, 2H) ).
- Step 1 Preparation of N-(1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)benzamide
- Step 2 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2' , 3'-Dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)benzamide
- N-(1′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl)benzamide (115mg, 0.394 mmol) was dissolved in 2mL of anhydrous N,N-dimethylformamide solution, sodium hydride (23.6mg, 0.591mmol) was added at 0°C, stirred for 30min, and (R)-2-(ethylene oxide-2 -Methyl)-1,2,3,4-tetrahydroisoquinoline (74.4mg, 0.394mmol) in N,N-dimethylformamide solution (2mL), moved to room temperature and reacted overnight.
- Step 1 Preparation of N-(1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)benzenesulfonamide
- Step 2 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2' Preparation of 3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)benzenesulfonamide
- N-(1′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl)benzenesulfonamide 80.0mg, 0.244mmol
- sodium hydride (14.6mg, 0.366mmol) was added at 0°C, stirred for 30min, and (R)-2-(ethylene oxide- A solution (1 mL) of 2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (46.1 mg, 0.244 mmol) in N,N-dimethylformamide was moved to room temperature and reacted overnight.
- Step 1 4-((1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)amino)piperidine Preparation of 1-tert-butyl carboxylate
- Step 2 (R)-4-((2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2 Preparation of',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)amino)piperidine-1-carboxylic acid tert-butyl ester
- Step 3 (R)-2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-7'-(piperidin-4-ylamino )-2',3'-Dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one
- Step 2 7'-((1-(cyclopropanecarbonyl)piperidin-4-yl)amino)-2',3'-dihydro-1'H-spiro[cyclopentane-1,4'-iso Preparation of quinoline]-1′-one
- Step 3 (R)-7′-((1-(cyclopropanecarbonyl)piperidin-4-yl)amino)-2′-(3-(3,4-dihydroisoquinoline-2(1H) -Yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopentane-1,4'-isoquinoline]-1'-one
- Example 8 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2 ′,3′-Dihydro-1′H-spiro[cyclobutane-1,4′-isoquinoline]-7′-yl)-1-methyl-1H-pyrazole-4-carboxamide
- Step 1 1-Methyl-N-(1′-oxo-2′,3′-dihydro-1′H-spiro[cyclobutane-1,4′-isoquinoline]-7′-yl ) Preparation of -1H-pyrazole-4-carboxamide
- Step 2 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2' , 3′-Dihydro-1′H-spiro[cyclobutane-1,4′-isoquinoline]-7′-yl)-1-methyl-1H-pyrazole-4-carboxamide
- Step 1 1-Methyl-N-(1′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl) Preparation of -1H-pyrazole-4-carboxamide
- Step 2 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2' , 3′-Dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl)-1-methyl-1H-pyrazole-4-carboxamide
- Step 2 (R)-1-Acetyl-N-(2′-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1′- Preparation of oxo-2',3'-dihydro-1'H-spiro[cyclobutane-1,4'-isoquinoline]-7'-yl)piperidine-4-carboxamide
- Step 2 (R)-1-Acetyl-N-(2′-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1′- Preparation of oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)piperidine-4-carboxamide
- reaction solution was poured into 10 mL saturated ammonium chloride solution and quenched, extracted with dichloromethane (15 mL ⁇ 3), combined the organic phases, evaporated the solvent under reduced pressure to obtain the crude product and separated by prep-HPLC to obtain the title compound.
- Example 12 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2 ′,3′-Dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl)tetrahydro-2H-pyran-4-carboxamide
- Step 1 N-(1′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl)tetrahydro-2H- Preparation of pyran-4-carboxamide
- Step 2 (R)-N-(2'-(3-(3,4-Dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2' , 3'-Dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)tetrahydro-2H-pyran-4-carboxamide
- N-(1′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-yl)tetrahydro-2H-pyran -4-formamide 250mg, 0.830mmol was dissolved in 5mL of anhydrous N,N-dimethylformamide, sodium hydride (67mg, 1.67mmol) was added at 0°C, and the reaction was continued for 1 hour at 0°C; then added (R)-2-(Ethylene oxide-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (159mg, 0.83mmol) in N,N-dimethylformamide solution ( 2mL).
- reaction was stirred overnight at room temperature, the reaction solution was poured into 10 mL of saturated ammonium chloride solution for quenching, extracted with dichloromethane, the organic phases were combined, and the solvent was evaporated under reduced pressure to obtain the crude product, which was prepared and separated by prep-HPLC to obtain the title compound.
- Example 1 of the present invention the compounds of Examples 13-34 were synthesized using different commercially available raw materials.
- the characterization parameters of these compounds are shown in Table 1:
- Reagents and consumables PRMT5, purchased from Active Motif, item number 31921; peptide substrate H4(1-21)S1ac, purchased from Gil Biochemical (Shanghai) Co., Ltd., item number 342095; [ 3 H]-SAM, Purchased from PerkinElmer, the article number is NET155V001MC; SAM, purchased from Sigma, the article number is A7007-100MG; SAH, purchased from Sigma Company, the article number is A9384-25MG; DTT, purchased from Shenggong Bioengineering (Shanghai) Co., Ltd. Limited company, the article number is A620058-0005.
- Corning-3657 purchased from Corning Company, the article number is 3657; Echo Qualified 384-Well, purchased from Labcyte Company, the article number is P-05525; FlashPlate, purchased from Perkin Elmer, the article number is SMP410J001PK.
- reaction buffer liquid components are 10mM Tris-HCl, pH 8.0; 0.01% Tween-20; 1mM DTT.
- the composition of the reaction stop solution was 125 ⁇ M 3 H-SAM solution.
- the compound was dissolved in 100% DMSO into a 10 mM stock solution, and then the compound was diluted to the required concentration on an Echo384-well plate.
- the peptide substrate and [ 3 H]-SAM were added to the 1-fold reaction buffer to form a 2.5-fold substrate solution (final concentrations of 100 nM and 250 nM, respectively).
- reaction stop solution 0.5 ⁇ L of reaction stop solution to each well of the 384-well reaction plate to stop the reaction. Take 25uL from each well of the test plate and transfer it to Flashplate, and place it at room temperature for 1h. Then wash the Flashpate plate 3 times with 0.1% Tween-20 solution.
- Inhibition rate (%) (maximum-sample value)/(maximum-minimum) ⁇ 100%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
- 一种通式(I)所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,A compound represented by general formula (I) or its isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug,其中,among them,环A选自芳基、杂芳基、环烷基和杂环基,所述芳基、杂芳基、环烷基和杂环基可被一个或多个选自卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、烷基磺酰基、氨基酰基、烷基氨基酰基、双烷基氨基、烯基、炔基、环烷基、杂环基、芳基、杂芳基和氧代基团的基团取代;Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl, and the aryl, heteroaryl, cycloalkyl and heterocyclic group may be one or more selected from halogen, hydroxy, alkyl, Haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, alkylsulfonyl, amino Substitution of acyl, alkylaminoacyl, dialkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and oxo groups;Cy选自芳基、杂芳基、环烷基和杂环基,所述芳基、杂芳基、环烷基和杂环基可被一个或多个选自卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、烷基磺酰基、氨基酰基、烷基氨基酰基、双烷基氨基、烯基、炔基、卤代烷基酰基、羟基烷基酰基、环烷基酰基、杂环基酰基、环烷基、杂环基、芳基、杂芳基和氧代基团的基团取代;Cy is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocyclyl. The aryl, heteroaryl, cycloalkyl, and heterocyclic group may be one or more selected from halogen, hydroxy, alkyl, and halogenated alkyl. Group, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, alkylsulfonyl, aminoacyl , Alkylamino acyl, dialkylamino, alkenyl, alkynyl, haloalkyl acyl, hydroxyalkyl acyl, cycloalkyl acyl, heterocyclyl acyl, cycloalkyl, heterocyclic, aryl, heteroaryl And oxo group substitution;R 1、R 2、R 3、R 4各自独立地选自氢、卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基和双烷基氨基; R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, Cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl and dialkylamino;R 5选自氢、烷基、卤代烷基、羟基烷基、烷基酰基、氨基酰基和烷基氨基酰基; R 5 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkylacyl, aminoacyl and alkylaminoacyl;X 1、X 2、X 3分别独立地选自N和C(R 6),其中R 6选自氢、卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、双烷基氨基和环烷基;和 X 1 , X 2 , and X 3 are each independently selected from N and C (R 6 ), wherein R 6 is selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, Hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, and cycloalkyl; andL选自-NH-、-S-、-O-、-C(O)NH-、-NHC(O)-、-OC(O)NH-、-NHC(O)O-、-S(O) 2NH-、-NHS(O) 2-、-C(O)-和-NHC(O)NH-。 L is selected from -NH-, -S-, -O-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -S(O ) 2 NH-, -NHS(O) 2 -, -C(O)- and -NHC(O)NH-.
- 根据权利要求1所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,The compound according to claim 1, or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof,其中环A选自C 6-12芳基、5-12元杂芳基、C 3-12环烷基和3-12元杂环基,所述C 6-12芳基、5-12元杂芳基、C 3-12环烷基和3-12元杂环基可被一个或多个选自卤素、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、单C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、C 1-6烷基磺酰基、氨基酰基、C 1-6烷基氨基酰基、双C 1-6烷基氨基、C 2-10烯基、C 2-10炔基、C 3-12环烷基、3-12元杂环基、6-12元芳基、5-12元杂芳基和 氧代基团的基团取代。 Wherein ring A is selected from C 6-12 aryl, 5-12 membered heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic group, the C 6-12 aryl, 5-12 membered heterocyclic group Aryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic group can be selected by one or more selected from halogen, hydroxyl, C 1-6 alkyl, halo C 1-6 alkyl, hydroxy C 1- 6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkyl acylamino, C 1-6 alkyl acyl, C 1-6 alkylsulfonyl, amino acyl, C 1-6 alkylamino acyl, bis C 1-6 alkylamino, C 2- Group substitution of 10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, 6-12 membered aryl, 5-12 membered heteroaryl and oxo group .
- 根据权利要求1或2所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,其中Cy选自C 6-12芳基、5-12元杂芳基、C 3-12环烷基和3-12元杂环基,所述C 6-12芳基、5-12元杂芳基、C 3-12环烷基和3-12元杂环基可被一个或多个选自卤素、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、单C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、C 1-6烷基磺酰基、氨基酰基、C 1-6烷基氨基酰基、双C 1-6烷基氨基、C 2-10烯基、C 2-10炔基、卤代C 1-6烷基酰基、羟基C 1-6烷基酰基、C 3-12环烷基酰基、3-12元杂环基酰基、C 3-12环烷基、3-12元杂环基、6-12元芳基、5-12元杂芳基和氧代基团的基团取代。 The compound or its isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug according to claim 1 or 2, wherein Cy is selected from C 6-12 aryl, 5-12 membered heteroaryl, C 3-12 cycloalkyl group and 3-12 membered heterocyclic group, the C 6-12 aryl group, 5-12 membered heteroaryl group, C 3-12 cycloalkyl group and 3-12 membered heterocyclic group can be One or more selected from halogen, hydroxy, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy Group, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkyl acylamino, C 1-6 alkyl acyl, C 1- 6 alkylsulfonyl group, an amino group, a C 1-6 alkylamino group, a di-C 1-6 alkylamino, C 2-10 alkenyl, C 2-10 alkynyl group, halo C 1-6 alkyl group , Hydroxy C 1-6 alkyl acyl, C 3-12 cycloalkyl acyl, 3-12 membered heterocyclyl acyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, 6-12 membered aryl group , 5-12 membered heteroaryl and oxo group substitutions.
- 根据权利要求1-3之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,其中R 1、R 2、R 3、R 4各自独立地选自氢、卤素、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、单C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基和双C 1-6烷基氨基。 The compound or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof according to any one of claims 1-3, wherein R 1 , R 2 , R 3 , and R 4 are each independently Selected from hydrogen, halogen, hydroxy, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, Hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkyl acylamino, C 1-6 alkyl acyl, amino acyl, C 1 -6 alkylaminoacyl and bis-C 1-6 alkylamino.
- 根据权利要求1-3之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,其中R 5选自氢、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基。 The compound according to any one of claims 1 to 3, or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, wherein R 5 is selected from hydrogen, C 1-6 alkyl, halogen Substituted C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkyl acyl, amino acyl, C 1-6 alkyl amino acyl.
- 根据权利要求1-3之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,其中通式(I)具有以下通式(Ia)的结构,The compound or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof according to any one of claims 1 to 3, wherein the general formula (I) has the structure of the following general formula (Ia) ,其中,Cy、L和环A具有权利要求1-3中所述的定义。Among them, Cy, L and ring A have the definitions described in claims 1-3.
- 一种药物组合物,其包含权利要求1至8之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药和可药用载体。A pharmaceutical composition comprising the compound according to any one of claims 1 to 8 or its isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug, and a pharmaceutically acceptable carrier.
- 权利要求1-8之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药或权利要求9所述的药物组合物在制备用于治疗PRMT5介导的疾病的药物中的应用。The compound of any one of claims 1-8 or its isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs or the pharmaceutical composition of claim 9 is prepared for the treatment of PRMT5 mediation The application of drugs for leading diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910550820 | 2019-06-24 | ||
CN201910550820.0 | 2019-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020259478A1 true WO2020259478A1 (en) | 2020-12-30 |
Family
ID=73850561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/097652 WO2020259478A1 (en) | 2019-06-24 | 2020-06-23 | Tricyclic compound as prmt5 inhibitor and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112125886B (en) |
WO (1) | WO2020259478A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022551947A (en) * | 2019-10-12 | 2022-12-14 | 南京聖和薬業股▲ふん▼有限公司 | Substituted tricyclic compounds as PRMT5 inhibitors and their applications |
WO2023223099A3 (en) * | 2022-05-20 | 2023-12-28 | Hangzhou Unogen Biotech, Ltd. | Prmt5 inhibitors and methods of treatment |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117242073A (en) * | 2021-04-02 | 2023-12-15 | 海思科医药集团股份有限公司 | PRMT5 inhibitors and uses thereof |
WO2023232025A1 (en) * | 2022-05-31 | 2023-12-07 | Hutchmed Limited | Tricyclic compounds and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014100716A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2017153515A1 (en) * | 2016-03-09 | 2017-09-14 | Ctxt Pty Limited | Tetrahydroisoquinolines as prmt5-inhibitors |
WO2018161922A1 (en) * | 2017-03-09 | 2018-09-13 | 中国科学院上海药物研究所 | Compound having prmt5 inhibitory activity, preparation for compound, and applications thereof |
WO2019094311A1 (en) * | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019173804A1 (en) * | 2018-03-09 | 2019-09-12 | Pharmablock Sciences (Nanjing), Inc. | Inhibitors of protein arginine methyltransferase 5 (prmt5), pharmaceutical products thereof, and methods thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9908887B2 (en) * | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
-
2020
- 2020-06-23 WO PCT/CN2020/097652 patent/WO2020259478A1/en active Application Filing
- 2020-06-24 CN CN202010584193.5A patent/CN112125886B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014100716A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2017153515A1 (en) * | 2016-03-09 | 2017-09-14 | Ctxt Pty Limited | Tetrahydroisoquinolines as prmt5-inhibitors |
WO2018161922A1 (en) * | 2017-03-09 | 2018-09-13 | 中国科学院上海药物研究所 | Compound having prmt5 inhibitory activity, preparation for compound, and applications thereof |
WO2019094311A1 (en) * | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019173804A1 (en) * | 2018-03-09 | 2019-09-12 | Pharmablock Sciences (Nanjing), Inc. | Inhibitors of protein arginine methyltransferase 5 (prmt5), pharmaceutical products thereof, and methods thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022551947A (en) * | 2019-10-12 | 2022-12-14 | 南京聖和薬業股▲ふん▼有限公司 | Substituted tricyclic compounds as PRMT5 inhibitors and their applications |
EP4043459A4 (en) * | 2019-10-12 | 2022-12-21 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Substituted tricyclic compound as prmt5 inhibitor and use thereof |
JP7301222B2 (en) | 2019-10-12 | 2023-06-30 | 南京聖和薬業股▲ふん▼有限公司 | Substituted tricyclic compounds as PRMT5 inhibitors and their applications |
AU2020363144B2 (en) * | 2019-10-12 | 2023-08-24 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Substituted tricyclic compound as PRMT5 inhibitor and use thereof |
WO2023223099A3 (en) * | 2022-05-20 | 2023-12-28 | Hangzhou Unogen Biotech, Ltd. | Prmt5 inhibitors and methods of treatment |
Also Published As
Publication number | Publication date |
---|---|
CN112125886B (en) | 2023-06-23 |
CN112125886A (en) | 2020-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10478423B2 (en) | Substituted indazole derivatives active as kinase inhibitiors | |
WO2020259478A1 (en) | Tricyclic compound as prmt5 inhibitor and application thereof | |
JP6966423B2 (en) | Condensed ring pyrimidine amino derivative, its production method, intermediate, pharmaceutical composition and application | |
US20110053982A1 (en) | Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors | |
WO2021218755A1 (en) | Shp2 inhibitor, and composition and use thereof | |
JP2024505732A (en) | Pyridopyrimidinone derivatives and their production methods and uses | |
US20110144159A1 (en) | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors | |
WO2020182018A1 (en) | Nitrogen heterocyclic compound, preparation method therefor and use thereof | |
CN113454081A (en) | Imidazopyridinyl compounds and their use for the treatment of proliferative diseases | |
AU2020363144B2 (en) | Substituted tricyclic compound as PRMT5 inhibitor and use thereof | |
ES2763424T3 (en) | Novel compounds of 3,4-dihydro-2H-isoquinolin-1-one and 2,3-dihydro-isoindol-1-one | |
WO2022171088A1 (en) | Pyrazolo[3,4-d]pyrimidin-3-one derivative | |
WO2021249324A1 (en) | Alkenyl pyrimidine compound, preparation method therefor, and application thereof | |
JP7175878B2 (en) | Novel benzimidazolone compounds and their medicinal uses | |
WO2022156788A1 (en) | Benzimidazole compound and use thereof | |
CN114591317A (en) | P2X3 inhibitors and uses thereof | |
WO2023011610A1 (en) | Benzodioxane compound, preparation method therefor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20830749 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20830749 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20830749 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 27.06.2022 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20830749 Country of ref document: EP Kind code of ref document: A1 |